Acrivon Therapeutics, Inc.
ACRV Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$1.72
KIRA · Stoqly’s AI analyst, in plain words
- Acrivon Therapeutics, Inc. lost $77.9M in fiscal 2025.
- Free cash flow was −$65.3M in fiscal 2025, — of revenue.
Market cap
$72.0M
P/E
—
Revenue
—
Net income
−$77.9M
Free cash flow
−$65.3M
Operating margin
—
Acrivon Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$77.9M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Acrivon Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 19, 2026
- Legal name
- Acrivon Therapeutics, Inc.
- CIK
- 0001781174
Acrivon Therapeutics, Inc. · ACRV
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$16.2M | −$31.2M | −$60.4M | −$80.6M | −$77.9M |
| Diluted EPS | −$9.32 | −$7.56 | −$2.74 | −$2.38 | −$2.02 |
| Cash | |||||
| Cash from operations | −$14.0M | −$30.1M | −$42.6M | −$65.7M | −$63.7M |
| Capital expenditure | $0.2M | $2.2M | $1.3M | $2.8M | $1.7M |
| Free cash flow | −$14.2M | −$32.3M | −$43.9M | −$68.4M | −$65.3M |
| Share count change | — | 136.4% | 435.6% | 53.1% | 14.0% |
| Debt and strength | |||||
| Cash and short-term investments | $99.6M | $128M | $127M | $179M | $119M |
| Shareholders' equity | −$23.8M | $170M | $121M | $177M | $113M |
| Current ratio | 34.5x | 20.3x | 9.7x | 10.6x | 7.7x |
| Returns and quality | |||||
| Return on equity | — | −42.5% | −41.4% | −54.1% | −53.9% |
| Return on tangible equity | — | −18.3% | −49.8% | −45.6% | −69.2% |
| Altman Z'' | 1.0 | 19.0 | 7.0 | 8.5 | 0.9 |
Insiders bought, 12 months
$0.1M
3 insiders
Insiders sold, 12 months
$0.0M
7 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Acrivon Therapeutics, Inc. · ACRV
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.72 a share, the company is worth $72.0M.
Source: SEC EDGAR XBRL filings (CIK 0001781174). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.